OR51F1 Antibody

What is OR51F1 and why is it significant for research?

OR51F1 (Olfactory Receptor Family 51 Subfamily F Member 1) belongs to the olfactory receptor family, which has gained significant research interest beyond olfactory tissues. Similar to other olfactory receptors like OR51E1, OR51F1 may have broad tissue expression patterns and potential roles in non-olfactory tissues. Understanding OR51F1 expression can provide insights into cellular functions across different tissue types and potentially identify novel biomarkers for various conditions, as has been demonstrated with related olfactory receptors .

What applications is the OR51F1 antibody validated for?

The OR51F1 antibody has been validated for multiple research applications including Western Blot (WB), Immunocytochemistry (ICC), Immunofluorescence (IF), and Enzyme-Linked Immunosorbent Assay (ELISA) . These applications enable researchers to detect OR51F1 protein expression in various experimental contexts, from protein lysates to intact cells and tissues, providing versatile options for experimental design.

What species reactivity has been confirmed for OR51F1 antibody?

The OR51F1 antibody has demonstrated reactivity with human, mouse, and rat samples . This cross-species reactivity is valuable for comparative studies and translational research, allowing investigators to examine OR51F1 expression across different model organisms and correlate findings with human samples.

What is the recommended protocol for immunohistochemical detection of OR51F1?

While specific protocols for OR51F1 immunohistochemistry must be optimized, researchers can adapt protocols used for other olfactory receptors. Based on methodologies used for related receptors like OR51E1 and OR51J1, tissue sections should be deparaffinized, rehydrated, and subjected to epitope retrieval (commonly using Tris-EDTA, pH 9 for approximately 20 minutes). After blocking endogenous peroxidases with H₂O₂ and non-specific binding with normal serum, the OR51F1 primary antibody should be applied for 45-60 minutes at room temperature in a humid chamber. Visualization can be performed using appropriate detection systems, followed by counterstaining with hematoxylin .

How should OR51F1 antibody be stored to maintain optimal performance?

For long-term storage, the OR51F1 antibody should be stored at -20°C for up to one year. For short-term storage and frequent use, it can be kept at 4°C for up to one month. It's crucial to avoid repeated freeze-thaw cycles to maintain antibody integrity and performance . The antibody is typically supplied in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide, which helps stabilize the protein .

How can I optimize co-localization studies using OR51F1 antibody with other protein markers?

Co-localization studies with OR51F1 antibody require careful optimization of fixation, permeabilization, and antibody incubation conditions. Based on approaches used with related olfactory receptors like OR51E1, researchers should consider:

• Testing multiple fixation protocols (4% paraformaldehyde, methanol, or acetone)

• Optimizing permeabilization conditions (0.1-0.5% Triton X-100)

• Using sequential rather than simultaneous antibody incubations to minimize cross-reactivity

• Employing appropriate controls including single-antibody staining and antibody absorption controls

In co-localization studies with OR51E1 and VMAT1 (SLC18A1), researchers have successfully identified distinct populations of cells expressing either or both markers . Similar approaches can be applied to OR51F1 co-localization studies to map its expression relative to other tissue-specific markers.

What subcellular localization patterns might be expected when using OR51F1 antibody?

Based on studies with related olfactory receptors, researchers should anticipate and be prepared to interpret multiple subcellular localization patterns when using OR51F1 antibody. OR51E1, for example, demonstrates cytoplasmic, membranous, and perinuclear immunostaining patterns in different cell types and conditions .

Cytoplasmic and membrane staining represent standard localization for many GPCRs, while perinuclear accumulation might reflect receptor internalization, trafficking, or degradation processes. Quantification should account for these distinct patterns, potentially using high-resolution imaging to distinguish between membrane-associated and intracellular receptor pools .

How can qRT-PCR be used to validate OR51F1 antibody specificity and complement protein expression studies?

To validate OR51F1 antibody specificity and complement immunodetection studies, researchers should:

• Design OR51F1-specific primers (typically 18-22 bp length with 50-60% GC content)

• Include appropriate housekeeping genes (e.g., beta-actin) for normalization

• Verify amplification efficiency (90-110%) using standard curve analysis

• Confirm specificity through melt curve analysis and no-RT controls

• Apply the Pfaffl method for accurate quantification that accounts for amplification efficiency

The qRT-PCR protocol should include initial denaturation at 95°C for 10 minutes, followed by 40 cycles of 95°C for 10 seconds and 60°C for 40 seconds, with subsequent melt curve analysis . Correlation between mRNA and protein levels provides stronger evidence for specific antibody detection.

What strategies can address potential cross-reactivity with other olfactory receptors?

Addressing cross-reactivity concerns with OR51F1 antibody requires systematic validation:

• Perform absorption tests using the immunizing peptide to confirm specificity

• Include tissues known to be negative for OR51F1 expression as controls

• Compare staining patterns with multiple OR51F1 antibodies from different manufacturers or different epitope targets

• Use OR51F1 knockout/knockdown models or cell lines for definitive validation

• Perform Western blot analysis to confirm detection of a protein with the expected molecular weight

When evaluating OR51E1 antibody specificity, researchers employed neutralization tests using specific blocking peptides and replacement of primary antibody with non-immune serum . These approaches effectively differentiated between specific and non-specific immunostaining.

How should immunohistochemical OR51F1 staining be quantified for rigorous statistical analysis?

For rigorous quantification of OR51F1 immunostaining, researchers should implement systematic scoring approaches:

• Intensity scoring: Use a standardized scale (0=negative, 1+=weak, 2+=moderate, 3+=strong) to grade staining intensity

• Distribution scoring: Quantify the percentage of positive cells in representative fields

• Subcellular pattern assessment: Record distinct patterns (membrane, cytoplasmic, perinuclear)

• High-power field analysis: Count immunoreactive cells per HPF (typically at 400× magnification)

• Principal Component Analysis: For complex datasets with multiple parameters, consider PCA to develop composite scores

For OR51J1 studies, researchers dichotomized expression into low (1+ and 2+) and high (3+) groups before correlation with clinicopathological features . Similar approaches could be applied to OR51F1 expression analysis.

How do expression patterns of OR51F1 compare with other olfactory receptors in non-olfactory tissues?

While specific data on OR51F1 tissue distribution must be determined experimentally, comparative analysis with related olfactory receptors provides valuable context. OR51E1 demonstrates extraordinarily broad tissue expression among human olfactory receptors, with expression reported in 13 different tissues . OR51J1 shows elevated expression in more than 20 cancer tissue types .

When designing studies to map OR51F1 expression, researchers should include tissue microarrays spanning multiple organ systems and apply consistent detection methods across samples. Correlation with publicly available transcriptomic databases can provide additional validation of protein expression patterns.

What controls are essential for validating OR51F1 antibody specificity in immunohistochemistry?

Essential controls for validating OR51F1 antibody specificity include:

• Peptide neutralization/blocking: Pre-incubation of antibody with the immunizing peptide should abolish specific staining

• Isotype controls: Replacement of primary antibody with non-immune IgG at equivalent concentration

• Positive tissue controls: Inclusion of tissues with confirmed OR51F1 expression

• Negative tissue controls: Inclusion of tissues known to lack OR51F1 expression

• Secondary antibody-only controls: Omission of primary antibody to detect non-specific binding

In OR51E1 studies, researchers employed neutralization tests with blocking peptides that effectively eliminated specific immunostaining in neuroendocrine cells while non-specific hepatic cell staining persisted, demonstrating the value of this validation approach .

How can I troubleshoot inconsistent OR51F1 antibody performance across different experimental systems?

Inconsistent antibody performance may result from multiple factors requiring systematic troubleshooting:

• Fixation optimization: Test multiple fixation protocols (4% PFA, methanol, acetone) and durations

• Antigen retrieval methods: Compare heat-induced (citrate, EDTA) vs. enzymatic retrieval methods

• Blocking optimization: Test different blocking agents (BSA, normal serum, commercial blockers)

• Antibody concentration titration: Perform serial dilutions to identify optimal concentration

• Incubation conditions: Vary temperature (4°C, RT, 37°C) and duration (1 hour to overnight)

• Detection system comparison: Compare different secondary antibodies or detection kits

Researchers studying olfactory receptors like OR51E1 have observed variability in staining patterns across different tissues and experimental conditions, necessitating protocol optimization for each specific application .

How might OR51F1 expression correlate with disease states based on patterns observed with other olfactory receptors?

Based on findings with related olfactory receptors, OR51F1 expression patterns may correlate with specific disease states, particularly cancer. OR51J1 demonstrates significantly elevated expression in breast cancer tissues (2.91-fold higher than normal tissues) and is expressed in more than 20 cancer types . Similarly, OR51E1 shows expression in prostate cancer tissues and metastases, with 94% of lymph node metastases and 87% of distant metastases expressing the receptor .

Researchers investigating OR51F1 in disease contexts should:

• Perform comprehensive tissue microarray analysis across multiple cancer types

• Correlate expression with clinicopathological parameters (grade, stage, receptor status)

• Evaluate expression in paired primary tumors and metastatic lesions

• Assess prognostic significance through survival analysis

• Investigate functional consequences of OR51F1 expression through in vitro models

What approaches can determine if amino acid variations in OR51F1 affect antibody binding and receptor function?

To investigate the impact of amino acid variations on OR51F1 antibody binding and receptor function, researchers should implement a multi-faceted approach:

• Epitope mapping: Identify the specific amino acid sequence recognized by the antibody

• Site-directed mutagenesis: Generate variants with specific amino acid substitutions

• Binding affinity assays: Compare antibody binding to wild-type and mutant receptors

• Trafficking analysis: Assess receptor localization using fluorescently-tagged constructs

• Functional assays: Evaluate signaling responses to potential ligands

Studies with OR51E1 have identified amino acid residues that significantly influence receptor trafficking and function, with single nucleotide polymorphisms affecting receptor activity . Similar approaches could reveal critical structural features of OR51F1.

How can OR51F1 antibody be integrated into multiplexed imaging approaches for complex tissue analysis?

Integrating OR51F1 antibody into multiplexed imaging requires careful optimization of multiple parameters:

• Antibody panel design: Select antibodies raised in different host species to avoid cross-reactivity

• Sequential staining protocols: Develop methods for serial staining, imaging, and signal removal

• Spectral unmixing: Apply appropriate algorithms to separate fluorophore signals with overlapping spectra

• Multispectral imaging systems: Utilize platforms capable of distinguishing multiple fluorophores

• Analytical frameworks: Implement computational approaches for quantifying co-expression patterns

Studies examining OR51E1 co-localization with markers like VMAT1 demonstrate the value of such approaches in defining distinct cell populations and understanding receptor expression in tissue context .